Cognios Beta Neutral Large Cap Fund LP Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Cognios Beta Neutral Large Cap Fund LP increased its stake in Pfizer Inc. (NYSE:PFE) by 4.3% during the 4th quarter, Holdings Channel reports. The firm owned 18,066 shares of the biopharmaceutical company’s stock after purchasing an additional 739 shares during the quarter. Cognios Beta Neutral Large Cap Fund LP’s holdings in Pfizer were worth $520,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares during the last quarter. Morgan Stanley increased its position in shares of Pfizer by 0.4% in the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Pfizer by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after purchasing an additional 5,185,453 shares during the last quarter. Invesco Ltd. increased its position in shares of Pfizer by 30.9% in the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after purchasing an additional 5,678,004 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in shares of Pfizer by 0.6% in the third quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after purchasing an additional 101,256 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.2 %

PFE stock traded down $0.06 on Wednesday, reaching $26.26. The company’s stock had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. The business has a fifty day simple moving average of $27.07 and a two-hundred day simple moving average of $28.52. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The firm has a market cap of $148.70 billion, a PE ratio of 72.97, a PEG ratio of 1.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the firm posted $1.14 earnings per share. The firm’s revenue was down 41.3% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. Pfizer’s payout ratio is 466.67%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.